Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor - Concepedia

Concepedia

Publication | Closed Access

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor

149

Citations

26

References

2015

Year

Kyriakos P. Papadopoulos, Randi Isaacs, Sanela Bilic, Kerstin Kentsch, Heather Huet, Matthias Hofmann, Drew Rasco, Nicole Kundamal, Zhongwhen Tang, Jennifer Cooksey,

Cancer Chemotherapy and Pharmacology

NanomedicineDrug TargetDrug TargetingDr5 ReceptorBiochemistryMedicineLiver PhysiologyHepatotoxicityPharmacotherapyPharmacologyDrug-induced Liver InjuryDrug Discovery

References

	Year	Citations

Page 1

Page 1